Aptevo Therapeutics (APVO) Enterprise Value (2016 - 2023)
Historic Enterprise Value for Aptevo Therapeutics (APVO) over the last 9 years, with Q3 2023 value amounting to -$19.1 million.
- Aptevo Therapeutics' Enterprise Value rose 1535.63% to -$19.1 million in Q3 2023 from the same period last year, while for Sep 2023 it was -$19.1 million, marking a year-over-year increase of 1535.63%. This contributed to the annual value of -$22.6 million for FY2022, which is 5111.55% up from last year.
- Per Aptevo Therapeutics' latest filing, its Enterprise Value stood at -$19.1 million for Q3 2023, which was up 1535.63% from -$21.0 million recorded in Q2 2023.
- Aptevo Therapeutics' Enterprise Value's 5-year high stood at -$9.5 million during Q2 2020, with a 5-year trough of -$62.9 million in Q2 2021.
- Moreover, its 5-year median value for Enterprise Value was -$27.5 million (2020), whereas its average is -$31.9 million.
- Its Enterprise Value has fluctuated over the past 5 years, first skyrocketed by 7242.85% in 2020, then tumbled by 56496.14% in 2021.
- Over the past 5 years, Aptevo Therapeutics' Enterprise Value (Quarter) stood at -$19.9 million in 2019, then plummeted by 126.06% to -$45.1 million in 2020, then decreased by 2.69% to -$46.3 million in 2021, then soared by 51.12% to -$22.6 million in 2022, then rose by 15.57% to -$19.1 million in 2023.
- Its last three reported values are -$19.1 million in Q3 2023, -$21.0 million for Q2 2023, and -$25.3 million during Q1 2023.